Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Economic impact of diagnostic testing
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Autoimmune pulmonary alveolar proteinosis

Economic impact of diagnostic testing

1 evidence topic · 1 source

Serum GM-CSF autoantibody testing: qualitative cost rationale

“can reduce the cost and morbidity associated with more invasive testing such as lung biopsies” (opens the source at this quote in a new tab)